Marks’ Sudden Departure From FDA Magnifies Uncertainty, Sends Biopharma Shares Down

The stock market—and biotech insiders—reacted negatively to the allegedly forced resignation of CBER Director Peter Marks, who said RFK Jr. does not seek “truth and transparency” but rather “subservient confirmation of his misinformation and lies.”